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1 Drug delivery systems
Although drug delivery may not attract the attention and
press coverage of some of the other disciplines involved in
drug discovery, it is an equally important issue in the de-
velopment of a successful product. Besides the choice of
the active drug substance (active pharmaceutical ingre-
dient - API), a responsible decision regarding the route
of administration and dosage form needs to be made. A
wrong choice can cause failure of therapy. Dosage forms
may be classified into:
• Conventional release;
• Modified release which can be delayed, controlled
or sustained.
The conventional release dosage forms are designed to
release the drug promptly after administration of a bo-
lus for immediate release. In contrast, modified release
dosage forms are designed to modulate drug release, de-
laying or prolonging the dissolution. Various technologies
may be employed to promote the gradual release of a
drug from a pharmaceutical form.
In the conventional therapy, aliquot quantities of a
drug are introduced into the system at specified time in-
tervals resulting in a considerable fluctuation on drug
concentration levels. However, an ideal dosage regimen
would be the one in which the concentration of the drug
is maintained between the limits of the therapeutic win-
dow at a constant level throughout all the treatment pe-
riod. Both situations can be graphically represented in
Figure 1.
The basic goal of this kind of therapy is to achieve a
steady state blood level that is therapeutically effective
and non-toxic for an extended period of time. The design
of a proper dosage regimen is an important element when
we want to accomplish this objective. An excellent drug
delivery system provides the right amount of drug or its
active metabolite to the target, at a time and rate that
optimizes its effect, without compromising patient safety.
Fig. 1 - Immediate versus controlled release dosage forms.
(MEC-Minimum effective concentration; MTC-Minimum toxic concentration)
in Steve I. Shen, Bhaskara R. Jasti, and Xiaoling Li, Standard Handbook of Biomedical Engineering and Design, Myer
Kutz (ed), Chapter 22: Design of Controlled-Release Drug Delivery Systems, Copyright The McGraw-Hill Companies,
Inc. 2003
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Controlling release to meet these requirements can in-
volve preventing release or delivery in enzymatically or
other hostile environments, targeting a specific location
to enhance therapeutic index, or prolonging delivery to
sustain an effect. Delivery on demand may also be re-
quired with biosensors linked to a delivery device like a
drug reservoir, for example. Pros and cons of controlled
Drug Delivery Systems (DDS) can be listed as follows:
• Improved patient convenience and compliance due
to less frequent drug administration.
• Reduction in fluctuation achieving a steady-state
level and therefore better control of disease condi-
tion.
• Increased safety margin of the drug due to better
control of plasma levels.
• Maximum utilization of drug enabling reduction in
total amount of dose administered.
• Reduction in health care cost through improved
therapy and shorter treatment period.
• Less frequency of dosing and reduction in personnel
time to dispense, administer and monitor patients.
• Better control of drug absorption can be obtained,
since the high blood level peaks that may be ob-
served after administration of a single dose corre-
sponding to a high bioavailability drug can be re-
duced.
• Decreased systemic availability in comparison to
immediate release conventional dosage forms; this
may be due to incomplete release or insufficient res-
idence time for complete release, for example.
• Poor in-vivo/in-vitro correlation.
• Possibility of dose dumping due to food interaction
with formulation and thus increased risk of toxicity.
• Retrieval of drug is difficult in case of toxicity, poi-
soning or hypersensitivity reaction.
• The physician has less flexibility in adjusting dosage
regimens. This is fixed by the dosage form design.
• Economic factors must also be assessed, since more
costly processes and equipment are involved in
manufacturing many of the sustained release forms.
Medication delivery to the systemic circulation
through the skin is an alternative to oral and parenteral
routes of administration. The first Transdermal Drug De-
livery Systems (TDDS) or drug loaded patches entered
the U.S. market in 1979 with the approval of the scopo-
lamine patch by the Food and Drug Administration (FDA)
for treatment of motion sickness. Today there are more
than twenty different types of medication patches avail-
able, and researchers are constantly striving to develop
additional and improved methods for transdermal deliv-
ery of medications. The great advantage lays on the fact
that it avoids first pass metabolism reactions which oc-
cur in the liver and gut wall resulting in a decrease on
drug bioavailability. TDDS (transdermal patches or trans-
dermal drug delivery systems) are designed to show a
perfect adhesion onto healthy and clean skin in order to
assure controlled drug delivery into the systemic circu-
lation. Problems linked with factors that affect percuta-
neous absorption must be studied and solved. This is the
purpose of several research teams working in universities
all over the world. Actually those problems are connected
with the following questions:
• Drug physicochemical properties: solubility, molec-
ular weight, partition coefficient;
• Stratum corneum characteristics like thickness and
lipophilicity;
• Concentration of the drug;
• Area of the applied field;
• Drug affinity for the skin.
Some promoters of percutaneous absorption have been
suggested. Chemical permeation enhancers, iontophore-
sis, sonophoresis and even micro or nano needles are
good examples. Different types of delivery systems in-
volve different technologies to sustain release and can be
listed as shown below:
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• Matrix systems: the matrix can be hydrophilic or
hydrophobic and drug release processes can involve
swelling of the polymer in use, drug diffusion and
matrix erosion;
• Reservoir systems;
• Osmotic pumps;
• Other systems – micro or nano sized needle arrays.
The improvement and innovation in the development
of controlled release systems strongly depend on select-
ing an appropriate agent capable of controlling drug re-
lease. The ideal agents for these preparations should en-
sure that the drug is released at the right place in the
right dose and at (or during) the required time. In addi-
tion, it must be said that with the advances in the field
of chronobiology, modern drug delivery approaches have
been elevated to a new concept of chronopharmacology,
which is the ability to deliver the therapeutic agent to a
patient in a pulsatile profile. New technology for medica-
tions delivering in a time-modulated fashion, by bedside
or ambulatory pumps, is being developed to manage hu-
man diseases, mainly chronic diseases.
Fig 2 - Time cycle when the diseases show their maximum effect
in Bisht R., Chronomodulated drug delivery system: A comprehensive review on the recent advances in a new sub-
discipline of ’chronopharmaceutics’. Asian J Pharm; 2011; 5:1-8
2 Controlled Drug Delivery at
CDRSP
In our research center, we are trying to “build” a model in
which levodopa (3,4-Dihydroxy-L-phenylalanine) is en-
trapped inside a sodium alginate membrane for skin ad-
ministration with a controlled mechanism of delivery. It
is expected that transdermal route would provide a sup-
ply of the drug to the blood stream without fluctuations
on therapeutic levels. This fact is very important in order
to avoid the typical on-off effects related to the thera-
peutics of Parkinson Disease, the disorder in which lev-
odopa is still the gold standard. In our labs, we produce
and characterize our drug loaded membranes; then, we
carry out the necessary dissolution assays required by the
Pharmacopoeias and recommended by the drug national
and international authorities. Finally, specific mathemat-
ical models are applied in order to understand the drug
release mechanism from the polymeric matrix.
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PONTIAC DEBUTS 2007 SOLSTICE GXP AT LA AUTO SHOW
The GXP version of the Solstice debuted at the Los Angeles Auto Show in January 2006.
The Pontiac Solstice Coupes are considered to be quite rare: There were a total of 1,266 Solstice Coupes
that were able to be manufactured before the production line in Wilmington, Delaware was shut down:
102 pre-production 2009 models, 1,152 sequentially-vin’d regular production 2009 models, and 12 pre-
production 2010 models. This is in contrast to over 64,000 of the Pontiac Solstice Convertibles that were
manufactured.
— Wikipedia
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